Literature DB >> 26296936

Copy number variations in multiple sclerosis and neuromyelitis optica.

Shinya Sato1, Ken Yamamoto2, Takuya Matsushita3, Noriko Isobe1, Yuji Kawano1, Kyoko Iinuma1, Masaaki Niino4, Toshiyuki Fukazawa5, Yuri Nakamura1, Mitsuru Watanabe1, Tomomi Yonekawa1, Katsuhisa Masaki1, Satoshi Yoshimura1, Hiroyuki Murai1, Ryo Yamasaki3, Jun-Ichi Kira1.   

Abstract

OBJECTIVE: To clarify the potential association of copy number variations (CNVs) with multiple sclerosis (MS) and neuromyelitis optica (NMO) in Japanese cases.
METHODS: Genome-wide association analyses of CNVs among 277 MS patients, 135 NMO/NMO spectrum disorder (NMOSD) patients, and 288 healthy individuals as a discovery cohort, and among 296 MS patients, 76 NMO/NMOSD patients, and 790 healthy individuals as a replication cohort were performed using high-density single nucleotide polymorphism microarrays.
RESULTS: A series of discovery and replication studies revealed that most identified CNVs were 5 to 50kb deletions at particular T cell receptor (TCR) gamma and alpha loci regions. Among these CNVs, a TCR gamma locus deletion was found in 16.40% of MS patients (p = 2.44E-40, odds ratio [OR] = 52.6), and deletion at the TCR alpha locus was found in 17.28% of MS patients (p = 1.70E-31, OR = 13.0) and 13.27% of NMO/NMOSD patients (p = 5.79E-20, OR = 54.6). These CNVs were observed in peripheral blood T-cell subsets only, suggesting the CNVs were somatically acquired. NMO/NMOSD patients carrying the CNV tended to be seronegative for anti-aquaporin-4 antibody or had significantly lower titers than those without CNV.
INTERPRETATION: Deletion-type CNVs at specific TCR loci regions contribute to MS and NMO susceptibility.
© 2015 American Neurological Association.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26296936     DOI: 10.1002/ana.24511

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  7 in total

Review 1.  De novo vs. inherited copy number variations in multiple sclerosis susceptibility.

Authors:  Kalthoum Tizaoui
Journal:  Cell Mol Immunol       Date:  2018-02-12       Impact factor: 11.530

Review 2.  Contributions of T cells in multiple sclerosis: what do we currently know?

Authors:  Borros Arneth
Journal:  J Neurol       Date:  2020-10-20       Impact factor: 6.682

Review 3.  Immunopathogenesis in Myasthenia Gravis and Neuromyelitis Optica.

Authors:  Zhen Wang; Yaping Yan
Journal:  Front Immunol       Date:  2017-12-12       Impact factor: 7.561

4.  Long-term use of interferon-β in multiple sclerosis increases Vδ1-Vδ2-Vγ9- γδ T cells that are associated with a better outcome.

Authors:  Guzailiayi Maimaitijiang; Mitsuru Watanabe; Koji Shinoda; Noriko Isobe; Yuri Nakamura; Katsuhisa Masaki; Takuya Matsushita; Yasunobu Yoshikai; Jun-Ichi Kira
Journal:  J Neuroinflammation       Date:  2019-09-13       Impact factor: 8.322

Review 5.  A Comprehensive Review on the Role of Genetic Factors in Neuromyelitis Optica Spectrum Disorder.

Authors:  Soudeh Ghafouri-Fard; Tahereh Azimi; Mohammad Taheri
Journal:  Front Immunol       Date:  2021-10-05       Impact factor: 7.561

6.  Copy number variations across the blood-brain barrier in multiple sclerosis.

Authors:  Sahl Khalid Bedri; Björn Evertsson; Mohsen Khademi; Faiez Al Nimer; Tomas Olsson; Jan Hillert; Anna Glaser
Journal:  Ann Clin Transl Neurol       Date:  2022-05-13       Impact factor: 5.430

7.  Association of Decreased Percentage of Vδ2+Vγ9+ γδ T Cells With Disease Severity in Multiple Sclerosis.

Authors:  Guzailiayi Maimaitijiang; Koji Shinoda; Yuri Nakamura; Katsuhisa Masaki; Takuya Matsushita; Noriko Isobe; Ryo Yamasaki; Yasunobu Yoshikai; Jun-Ichi Kira
Journal:  Front Immunol       Date:  2018-04-10       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.